Mathilde Pohin

Mathilde Pohin

Auto-generated profile, based on publicly available information

Mathilde Pohin

CHU de Bordeaux, University of Bordeaux

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Immunity
Verified
Journal Article
Closed access
MFMatthias Friedrich
Matthias Friedrich
MPMathilde Pohin
Mathilde Pohin
FPFiona Powrie
Fiona Powrie

21 October 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MFMatthias Friedrich
Matthias Friedrich
MPMathilde Pohin
Mathilde Pohin
MJMatthew A. Jackson
Matthew A. Jackson
IKIlya Korsunsky
Ilya Korsunsky
SBSamuel J. Bullers
Samuel J. Bullers
STSimon P. Travis
Simon P. Travis
Current inflammatory bowel disease (IBD) therapies are ineffective in a high proportion of patients. Combining bulk and single-cell transcriptomics, quantitative histopathology and in situ localization across three cohorts of patients with IBD (total n = 376), we identify coexpressed gene modules within the heterogeneous tissular inflammatory response in IBD that map to distinct histopathological and cellular features (pathotypes). One of these pathotypes is defined by high neutrophil infiltration, activation of fibroblasts and vascular remodeling at sites of deep ulceration. Activated fibroblasts in the ulcer bed display neutrophil-chemoattractant properties that are IL-1R, but not TNF, dependent. Pathotype-associated neutrophil and fibroblast signatures are increased in nonresponders to several therapies across four independent cohorts (total n = 343). The identification of distinct, localized, tissular pathotypes will aid precision targeting of current therapeutics and provides a biological rationale for IL-1 signaling blockade in ulcerating disease.

6 July 2015 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
HRHanitriniaina Rabeony
Hanitriniaina Rabeony
MPMathilde Pohin
Mathilde Pohin
PVPhilippe Vasseur
Philippe Vasseur
IPIsabelle Petit‐Paris
Isabelle Petit‐Paris
JJJean-François Jégou
Jean-François Jégou
FMFranck Morel
Franck Morel

28 April 2016 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
MPMathilde Pohin
Mathilde Pohin
WGWilliam Guesdon
William Guesdon
AMAdela Andrine Tagne Mekouo
Adela Andrine Tagne Mekouo
HRHanitriniaina Rabeony
Hanitriniaina Rabeony
IPIsabelle Paris
Isabelle Paris
JJJean-François Jégou
Jean-François Jégou
Oncostatin M (OSM) has been reported to be overexpressed in psoriasis skin lesions and to exert proinflammatory effects in vitro on human keratinocytes. Here, we report the proinflammatory role of OSM in vivo in a mouse model of skin inflammation induced by intradermal injection of murine OSM‐encoding adenovirus (AdOSM) and compare with that induced by IL‐6 injection. Here, we show that OSM potently regulates the expression of genes involved in skin inflammation and epidermal differentiation in murine primary keratinocytes. In vivo, intradermal injection of AdOSM in mouse ears provoked robust skin inflammation with epidermal thickening and keratinocyte proliferation, while minimal effect was observed after AdIL‐6 injection. OSM overexpression in the skin increased the expression of the S100A8/9 antimicrobial peptides, CXCL3, CCL2, CCL5, CCL20, and Th1/Th2 cytokines, in correlation with neutrophil and macrophage infiltration. In contrast, OSM downregulated the expression of epidermal differentiation genes, such as cytokeratin‐10 or filaggrin. Collectively, these results support the proinflammatory role of OSM when it is overexpressed in the skin. However, OSM expression was not required in the murine model of psoriasis induced by topical application of imiquimod, as demonstrated by the inflammatory phenotype of OSM‐deficient mice or wild‐type mice treated with anti‐OSM antibodies.

16 February 2023 in The EMBO Journal
Verified
Journal Article
Open access
FRFelix Clemens Richter
Felix Clemens Richter
MFMatthias Friedrich
Matthias Friedrich
NKNadja Kampschulte
Nadja Kampschulte
KPKlara Piletic
Klara Piletic
GAGhada Alsaleh
Ghada Alsaleh
KSKatja Simon
Katja Simon
Lipids play a major role in inflammatory diseases by altering inflammatory cell functions, either through their function as energy substrates or as lipid mediators such as oxylipins. Autophagy, a lysosomal degradation pathway that limits inflammation, is known to impact on lipid availability, however, whether this controls inflammation remains unexplored. We found that upon intestinal inflammation visceral adipocytes upregulate autophagy and that adipocyte‐specific loss of the autophagy gene Atg7 exacerbates inflammation. While autophagy decreased lipolytic release of free fatty acids, loss of the major lipolytic enzyme Pnpla2/Atgl in adipocytes did not alter intestinal inflammation, ruling out free fatty acids as anti‐inflammatory energy substrates. Instead, Atg7 ‐deficient adipose tissues exhibited an oxylipin imbalance, driven through an NRF2‐mediated upregulation of Ephx1 . This shift reduced secretion of IL‐10 from adipose tissues, which was dependent on the cytochrome P450‐EPHX pathway, and lowered circulating levels of IL‐10 to exacerbate intestinal inflammation. These results suggest an underappreciated fat‐gut crosstalk through an autophagy‐dependent regulation of anti‐inflammatory oxylipins via the cytochrome P450‐EPHX pathway, indicating a protective effect of adipose tissues for distant inflammation.

1 September 2016 in The American Journal of Pathology
Verified
Journal Article
Closed access
PVPhilippe Vasseur
Philippe Vasseur
LSLaura Serres
Laura Serres
JJJean-François Jégou
Jean-François Jégou
MPMathilde Pohin
Mathilde Pohin
ADAdriana Delwail
Adriana Delwail
JLJean-Claude Lecron
Jean-Claude Lecron